XML 249 R176.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable segments - Operating Segment Items (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of operating segments [line items]      
Revenue $ 4,528,761 $ 7,467,490 $ 10,710,578
Cost of sales (3,201,654) (4,392,436) (4,973,953)
Administrative expenses (185,959) (175,765) (142,644)
Finance expense (197,544) (138,402) (86,651)
Depreciation and amortization expense (342,424) (280,787) (244,458)
Interest in the income of associates and joint ventures accounted for by the equity method 11,025 593 20,159
Income before taxes 974,414 2,807,018 5,486,496
Income tax benefit (expense) (282,573) (1,876,751) (1,572,212)
Net income 691,841 930,267 3,914,284
Assets 11,495,569 10,778,837 10,819,101
Investment accounted for under the equity method 585,794 86,417 54,386
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts (1,181,113) 2,785,385 1,757,581
Other Liabilities 6,297,502 6,301,408 5,887,100
Impairment loss of non-financial assets recognized in income (7,134) (47,068) (42,233)
Cash flows from (used in) operating activities 1,274,678 (196,639) 4,077,595
Cash flows used in investing activities (1,213,992) (1,481,493) (909,401)
Cash flows from (used in) financing activities 282,383 66,261 (2,002,969)
Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets (639) (202) (3,369)
Operating segments      
Disclosure of operating segments [line items]      
Revenue 4,528,761 7,467,490 10,710,578
Cost of sales (3,201,654) (4,392,436) (4,973,953)
Administrative expenses 0 0 0
Finance expense 0 0 0
Depreciation and amortization expense (342,424) (280,787) (244,458)
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Income before taxes 1,327,107 3,075,054 5,736,625
Income tax benefit (expense) 0 0 0
Net income 1,327,107 3,075,054 5,736,625
Assets 0 0 0
Investment accounted for under the equity method 0 0 0
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts 0 0 0
Other Liabilities 0 0 0
Impairment loss of non-financial assets recognized in income 0 0 0
Cash flows from (used in) operating activities 0 0 0
Cash flows used in investing activities 0 0 0
Cash flows from (used in) financing activities 0 0 0
Operating segments | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets 0 0 0
Unallocated amounts      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Cost of sales 0 0 0
Administrative expenses (185,959) (175,765) (142,644)
Finance expense (197,544) (138,402) (86,651)
Depreciation and amortization expense 0 0 0
Interest in the income of associates and joint ventures accounted for by the equity method 11,025 593 20,159
Income before taxes (352,693) (268,036) (250,129)
Income tax benefit (expense) (282,573) (1,876,751) (1,572,212)
Net income (635,266) (2,144,787) (1,822,341)
Assets 11,495,569 10,778,837 10,819,101
Investment accounted for under the equity method 585,794 86,417 54,386
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts (1,181,113) 2,785,385 1,757,581
Other Liabilities 6,297,502 6,301,408 5,887,100
Impairment loss of non-financial assets recognized in income (7,134) (47,068) (42,233)
Cash flows from (used in) operating activities 1,274,678 (196,639) 4,077,595
Cash flows used in investing activities (1,213,992) (1,481,493) (909,401)
Cash flows from (used in) financing activities 282,383 66,261 (2,002,969)
Unallocated amounts | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets (639) (202) (3,369)
Specialty plant nutrients      
Disclosure of operating segments [line items]      
Revenue 941,940 913,912 1,172,334
Cost of sales (775,152) (691,509) (722,261)
Administrative expenses 0 0 0
Finance expense 0 0 0
Depreciation and amortization expense (72,211) (70,342) (63,321)
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Income before taxes 166,788 222,403 450,073
Income tax benefit (expense) 0 0 0
Net income 166,788 222,403 450,073
Assets 0 0 0
Investment accounted for under the equity method 0 0 0
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts 0 0 0
Other Liabilities 0 0 0
Impairment loss of non-financial assets recognized in income 0 0 0
Cash flows from (used in) operating activities 0 0 0
Cash flows used in investing activities 0 0 0
Cash flows from (used in) financing activities 0 0 0
Specialty plant nutrients | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets
Iodine and its derivatives      
Disclosure of operating segments [line items]      
Revenue 968,312 892,151 754,339
Cost of sales (444,904) (355,717) (282,100)
Administrative expenses 0 0 0
Finance expense 0 0 0
Depreciation and amortization expense (57,038) (53,140) (53,734)
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Income before taxes 523,408 536,434 472,239
Income tax benefit (expense) 0 0 0
Net income 523,408 536,434 472,239
Assets 0 0 0
Investment accounted for under the equity method 0 0 0
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts 0 0 0
Other Liabilities 0 0 0
Impairment loss of non-financial assets recognized in income 0 0 0
Cash flows from (used in) operating activities 0 0 0
Cash flows used in investing activities 0 0 0
Cash flows from (used in) financing activities 0 0 0
Iodine and its derivatives | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets
Lithium and its derivatives      
Disclosure of operating segments [line items]      
Revenue 2,241,250 5,180,114 8,152,939
Cost of sales (1,666,328) (2,955,669) (3,636,852)
Administrative expenses 0 0 0
Finance expense 0 0 0
Depreciation and amortization expense (187,538) (124,010) (88,510)
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Income before taxes 574,922 2,224,445 4,516,087
Income tax benefit (expense) 0 0 0
Net income 574,922 2,224,445 4,516,087
Assets 0 0 0
Investment accounted for under the equity method 0 0 0
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts 0 0 0
Other Liabilities 0 0 0
Impairment loss of non-financial assets recognized in income 0 0 0
Cash flows from (used in) operating activities 0 0 0
Cash flows used in investing activities 0 0 0
Cash flows from (used in) financing activities 0 0 0
Lithium and its derivatives | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets
Industrial chemicals      
Disclosure of operating segments [line items]      
Revenue 78,155 175,223 165,200
Cost of sales (47,453) (141,351) (112,247)
Administrative expenses 0 0 0
Finance expense 0 0 0
Depreciation and amortization expense (6,328) (15,232) (14,724)
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Income before taxes 30,702 33,872 52,953
Income tax benefit (expense) 0 0 0
Net income 30,702 33,872 52,953
Assets 0 0 0
Investment accounted for under the equity method 0 0 0
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts 0 0 0
Other Liabilities 0 0 0
Impairment loss of non-financial assets recognized in income 0 0 0
Cash flows from (used in) operating activities 0 0 0
Cash flows used in investing activities 0 0 0
Cash flows from (used in) financing activities 0 0 0
Industrial chemicals | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets
Potassium      
Disclosure of operating segments [line items]      
Revenue 270,783 279,050 437,180
Cost of sales (236,390) (219,597) (193,581)
Administrative expenses 0 0 0
Finance expense 0 0 0
Depreciation and amortization expense (19,275) (18,006) (24,043)
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Income before taxes 34,393 59,453 243,599
Income tax benefit (expense) 0 0 0
Net income 34,393 59,453 243,599
Assets 0 0 0
Investment accounted for under the equity method 0 0 0
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts 0 0 0
Other Liabilities 0 0 0
Impairment loss of non-financial assets recognized in income 0 0 0
Cash flows from (used in) operating activities 0 0 0
Cash flows used in investing activities 0 0 0
Cash flows from (used in) financing activities 0 0 0
Potassium | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets
Other products and services      
Disclosure of operating segments [line items]      
Revenue 28,321 27,040 28,586
Cost of sales (31,427) (28,593) (26,912)
Administrative expenses 0 0 0
Finance expense 0 0 0
Depreciation and amortization expense (34) (57) (126)
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Income before taxes (3,106) (1,553) 1,674
Income tax benefit (expense) 0 0 0
Net income (3,106) (1,553) 1,674
Assets 0 0 0
Investment accounted for under the equity method 0 0 0
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts 0 0 0
Other Liabilities 0 0 0
Impairment loss of non-financial assets recognized in income 0 0 0
Cash flows from (used in) operating activities 0 0 0
Cash flows used in investing activities 0 0 0
Cash flows from (used in) financing activities 0 0 0
Other products and services | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets
Reportable segments      
Disclosure of operating segments [line items]      
Revenue 4,528,761 7,467,490 10,710,578
Cost of sales (3,201,654) (4,392,436) (4,973,953)
Administrative expenses 0 0 0
Finance expense 0 0 0
Depreciation and amortization expense (342,424) (280,787) (244,458)
Interest in the income of associates and joint ventures accounted for by the equity method 0 0 0
Income before taxes 1,327,107 3,075,054 5,736,625
Income tax benefit (expense) 0 0 0
Net income 1,327,107 3,075,054 5,736,625
Assets 0 0 0
Investment accounted for under the equity method 0 0 0
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts 0 0 0
Other Liabilities 0 0 0
Impairment loss of non-financial assets recognized in income 0 0 0
Cash flows from (used in) operating activities 0 0 0
Cash flows used in investing activities 0 0 0
Cash flows from (used in) financing activities 0 0 0
Reportable segments | Impairment provision for doubtful receivables      
Disclosure of operating segments [line items]      
Financial Assets 0 0 0
Parent      
Disclosure of operating segments [line items]      
Revenue 4,528,761   10,710,578
Assets 9,794,433 8,824,362  
Other Liabilities 4,633,614 4,383,163  
Parent | Operating segments      
Disclosure of operating segments [line items]      
Revenue 4,528,761 7,467,490 10,710,578
Parent | Unallocated amounts      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Parent | Specialty plant nutrients      
Disclosure of operating segments [line items]      
Revenue 941,940 913,912 1,172,334
Parent | Iodine and its derivatives      
Disclosure of operating segments [line items]      
Revenue 968,312 892,151 754,339
Parent | Lithium and its derivatives      
Disclosure of operating segments [line items]      
Revenue 2,241,250 5,180,114 8,152,939
Parent | Industrial chemicals      
Disclosure of operating segments [line items]      
Revenue 78,155 175,223 165,200
Parent | Potassium      
Disclosure of operating segments [line items]      
Revenue 270,783 279,050 437,180
Parent | Other products and services      
Disclosure of operating segments [line items]      
Revenue 28,321 27,040 28,586
Parent | Reportable segments      
Disclosure of operating segments [line items]      
Revenue 4,528,761 7,467,490 10,710,578
Other Operating Segment      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Operating segments      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Unallocated amounts      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Specialty plant nutrients      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Iodine and its derivatives      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Lithium and its derivatives      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Industrial chemicals      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Potassium      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Other products and services      
Disclosure of operating segments [line items]      
Revenue 0 0 0
Other Operating Segment | Reportable segments      
Disclosure of operating segments [line items]      
Revenue $ 0 $ 0 $ 0